How it Works

One injection: Up to 36 months of CONTINUOUS CALM™ with less inflammation

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is an intravitreal implant designed to treat chronic non-infectious uveitis affecting the posterior segment. The YUTIQ implant steadily delivers a low therapeutic dose of long-acting steroid inside the eye directly to where it’s needed. This long-term, durable treatment may reduce recurrence for up to 36 months.

A uveitis treatment designed for the long term

If you and your eye doctor have identified symptoms of uveitis affecting the posterior segment and decided to move forward with YUTIQ, treatment awaits with lasting results.

YUTIQ is a tiny implant that is placed in the eye, designed to deliver a sustained release of medicine for up to 36 months. Working within the eye, YUTIQ delivers a low, continuous dose of medicine.

This close-up view shows the small size of the YUTIQ implant compared to a dime.

YUTIQ is a proven single-injection treatment for chronic non-infectious uveitis affecting the back of the eye (uveitis affecting the posterior segment). In a clinical trial, patients with YUTIQ had up to a 77% decrease in uveitis recurrence at 6 months. There were similar results at 12 months, where patients with YUTIQ had up to a 67% decrease in uveitis recurrence.1

YUTIQ is designed to last longer than
other treatments, so you may have
fewer injection appointments.

Questions to ask
your doctor about
YUTIQ

Find an eye doctor

Watch real patients
describe their
YUTIQ journey

The idea that I wouldn’t have to submit my eyeballs, or my psyche, to the trauma of receiving injections every 8 weeks was my main motivation for agreeing to YUTIQ treatment.”

– Christine, a YUTIQ patient

One patient’s experience; individual results may vary.

NEXT: Procedure
Expectations and Prep

NEXT: Procedure Expectations and Prep

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

YUTIQ® contains a corticosteroid and is for the treatment of patients with chronic, non-infectious uveitis affecting the back of the eye.

Important Safety Information

Do not take YUTIQ if:

  • You have, or suspect you have, an eye infection.
  • If you have been told you are allergic to any of the ingredients in YUTIQ.

Indication

YUTIQ® contains a corticosteroid and is for the treatment of patients with chronic, non-infectious uveitis affecting the back of the eye.

Important Safety Information

Do not take YUTIQ if:
  • You have, or suspect you have, an eye infection.
  • If you have been told you are allergic to any of the ingredients in YUTIQ.
YUTIQ may cause serious side effects, including:
  • Injection-related effects, steroid-related effects and movement of the implant.
  • Call your doctor if your eye becomes red, sensitive to light, painful or if your vision changes or becomes blurred.
  • You may experience temporary blurred vision. Do not drive or use machines until your vision clears.
  • The most common side effects in the eye were cataract and increased pressure in the eye. The most common side effects not related to the eye were upper respiratory infection, high blood pressure and joint pain.
  • If you are pregnant, become pregnant or consider breastfeeding after having received YUTIQ inform your doctor immediately.
Please see full Prescribing Information for YUTIQ at yutiq.com/pi/.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

This site is intended for US residents only. YUTIQ is a registered trademark of Alimera Sciences, Inc.

CONTINUOUS CALM and CONTINUOUS MICRODOSING are trademarks of Alimera Sciences, Inc.

Copyright © 2024 Alimera Sciences, Inc. All rights reserved. 1-844-445-8843. US-YTQ-MMM-0029

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full US Prescribing Information.
    Alimera Sciences, Inc. June 2023.

References

  1. What is Uveitis?. Prevent Blindness. Updated June 21, 2021. Accessed November 28, 2023. 

https://preventblindness.org/wp-content/uploads/2021/06/FS119-Uveitisshort.pdf